-
Listing
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLees meerEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lees meerThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLees meerThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
- Reglementen
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lees meerShaping capital markets for future generations
-
Listing
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLees meerEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lees meerThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLees meerThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
- Reglementen
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lees meerShaping capital markets for future generations
- Home
- About
- Media centre
- Bell en Gong Archief
- Hovione
Hovione
02/10/2015
Hovione rings the closing bell to celebrate the listing of €40 million in Bonds
To celebrate the listing of €40 million in bonds, Hovione rang the Closing Bell. He was accompanied by management team, along with the Euronext team. Hovione is a Pharmaceutical Company dedicated to helping Pharmaceutical Customers bring new and off-patent drugs to market.